Bio-Thera and Dr. Reddy's Execute Exclusive Commercialization Agreement for BAT2206, a Proposed Stelara® Biosimilar, and BAT2506, a Proposed Simponi® Biosimilar, for Southeast Asia

Core Viewpoint - Bio-Thera Solutions and Dr. Reddy's Laboratories have entered into exclusive commercialization and license agreements for two proposed biosimilars, BAT2206 and BAT2506, targeting Southeast Asia and Colombia [1][2][3] Group 1: Agreements and Responsibilities - Bio-Thera will handle the development, manufacturing, and supply of BAT2206 and BAT2506, while Dr. Reddy's will seek regulatory approvals and manage commercialization in Southeast Asia, including countries like Cambodia, Indonesia, Malaysia, Philippines, Thailand, and Vietnam [2][3] - Dr. Reddy's will also gain exclusive commercial rights to BAT2206 in Colombia [2] Group 2: Product Information - BAT2206 is a proposed biosimilar to Stelara®, targeting conditions like Crohn's disease and ulcerative colitis, and is currently approved in the EU for multiple indications including moderate to severe plaque psoriasis and active psoriatic arthritis [4] - BAT2506 is a proposed biosimilar to Simponi®, which is used for moderate to severe rheumatoid arthritis and carries a Boxed Warning for serious infections and malignancy [5] Group 3: Company Background - Bio-Thera Solutions is a biopharmaceutical company based in Guangzhou, China, focused on developing innovative therapies and biosimilars for various diseases, including cancer and autoimmune disorders [6][7] - Dr. Reddy's Laboratories, headquartered in Hyderabad, India, is a global pharmaceutical company committed to providing access to affordable medicines, with a diverse portfolio including APIs, generics, and biosimilars [8]